BioMarin Pharmaceutical (NASDAQ:BMRN) versus NeuroBo Pharmaceuticals (NASDAQ:NRBO) Head-To-Head Contrast

NeuroBo Pharmaceuticals (NASDAQ:NRBO) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Profitability

This table compares NeuroBo Pharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroBo Pharmaceuticals	N/A	-189.12%	-122.31%
BioMarin Pharmaceutical	14.96%	9.91%	7.65%

Risk and Volatility

NeuroBo Pharmaceuticals has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for NeuroBo Pharmaceuticals and BioMarin Pharmaceutical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroBo Pharmaceuticals	0	0	1	0	3.00
BioMarin Pharmaceutical	0	7	17	0	2.71

NeuroBo Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 624.64%. BioMarin Pharmaceutical has a consensus price target of $94.00, indicating a potential upside of 66.90%. Given NeuroBo Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe NeuroBo Pharmaceuticals is more favorable than BioMarin Pharmaceutical.

Valuation & Earnings

This table compares NeuroBo Pharmaceuticals and BioMarin Pharmaceutical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroBo Pharmaceuticals	N/A	N/A	-$12.47 million	N/A	N/A
BioMarin Pharmaceutical	$2.85 billion	3.76	$167.65 million	$2.20	25.60

BioMarin Pharmaceutical has higher revenue and earnings than NeuroBo Pharmaceuticals.

Insider & Institutional Ownership

1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. 1.1% of NeuroBo Pharmaceuticals shares are owned by insiders. Comparatively, 1.9% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats NeuroBo Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company’s therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.